Table A8.

Summary of geometric mean increase (GMI) estimates for antibodies targeting respiratory syncytial virus (RSV) of group A and B from included studies. If the immunogenicity of reported vaccines was provided in a validation study, the latter was included in the reported values.

Study	Vaccine	Day	GMI RSV A	GMI RSV B
Feldman et al. [80]	RSVPreF3	31	9.8 Range: 8.9–10.6	8.3 Range: 8.1–10.2
Falsey et al. [82]	Ad26.RSV.preF	15	12.1	9.4
Papi et al. [81]	RSVPreF3	30	10.2 Range: 9.5–11	8.6 Range: 8.0–9.2
Walsh et al. [52] (from Baber et al. [117])	RSVpreF	30	10.2	12.3
Wilson et al. [51] (from Chen et al.) [118]	mRNA-1345	30	Range: 12.1–16.6	Range: 8.7–12.6
Falloon et al. [83]	MEDI7510	End of season	4.6 Range: 4.3–4.9
Wilson et al. [85]	mRNA-1345	30	10.1	6.4